Thymoquinone-based nanotechnology for cancer therapy: promises and challenges

dc.contributor.authorBallout, Farah
dc.contributor.authorHabli, Zeina S.
dc.contributor.authorRahal, Omar Nasser
dc.contributor.authorFatfat, Maamoun
dc.contributor.authorGali-Muhtasib, Hala Uthman
dc.contributor.departmentDepartment of Biology
dc.contributor.departmentAnatomy, Cell Biology, and Physiological Sciences
dc.contributor.facultyFaculty of Arts and Sciences (FAS)
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:20:41Z
dc.date.available2025-01-24T11:20:41Z
dc.date.issued2018
dc.description.abstractThymoquinone (TQ), the active ingredient of black seed, is a promising anticancer molecule that inhibits cancer cell growth and progression in vitro and in vivo. Despite the promising anticancer activities of TQ, its translation to the clinic is limited by its poor bioavailability and hydrophobicity. As such, we and others encapsulated TQ in nanoparticles to improve its delivery and limit undesirable cytotoxicity. These TQ-nanoparticle formulations showed improved anticancer and anti-inflammatory activities when compared with free TQ. Here, we provide an overview of the various TQ-nanoparticle formulations, highlight their superior efficacy and discuss up-to-date solutions to further enhance TQ bioavailability and anticancer activity, thus improving potential for clinical translation. © 2018 Elsevier Ltd
dc.identifier.doihttps://doi.org/10.1016/j.drudis.2018.01.043
dc.identifier.eid2-s2.0-85041598568
dc.identifier.pmid29374534
dc.identifier.urihttp://hdl.handle.net/10938/25099
dc.language.isoen
dc.publisherElsevier Ltd
dc.relation.ispartofDrug Discovery Today
dc.sourceScopus
dc.subjectAnimals
dc.subjectAntineoplastic agents
dc.subjectBenzoquinones
dc.subjectHumans
dc.subjectNanoparticles
dc.subjectNanotechnology
dc.subjectNeoplasms
dc.subjectChitosan
dc.subjectCyclodextrin
dc.subjectLiposome
dc.subjectMacrogol
dc.subjectNiosome
dc.subjectPolycaprolactone
dc.subjectPolyglactin
dc.subjectPolymer
dc.subjectPolystyrene
dc.subjectPovidone
dc.subjectSolid lipid nanoparticle
dc.subjectThymoquinone
dc.subjectAntineoplastic agent
dc.subjectBenzoquinone derivative
dc.subjectNanoparticle
dc.subjectAntineoplastic activity
dc.subjectCancer inhibition
dc.subjectCancer therapy
dc.subjectDrug bioavailability
dc.subjectDrug efficacy
dc.subjectDrug formulation
dc.subjectHuman
dc.subjectLiposomal delivery
dc.subjectNanoencapsulation
dc.subjectNanopharmaceutics
dc.subjectNonhuman
dc.subjectReview
dc.subjectAnimal
dc.subjectNeoplasm
dc.titleThymoquinone-based nanotechnology for cancer therapy: promises and challenges
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2018-8261.pdf
Size:
358.31 KB
Format:
Adobe Portable Document Format